Intermittent docetaxel chemotherapy displayed non-inferiority in 1-year survival compared to continuous treatment for patients with castration-resistant prostate cancer (CRPC), according to a study presented at the American Society of Clinical Oncology (ASCO)’s 2016 meeting.1
In a randomized, phase 3 study, 187 patients were assigned to receive docetaxel for either 12 weeks followed by a pause until disease progression, or continuous treatment until discontinuation. Patients received the drug at a rate of 35 mg/m2 per week or 75mg/m2 every 3 weeks.
Of 156 eligible patients, 50% in each cohort, 1-year survival was 75.8% for those receiving intermittent treatment, and 72.6% for those receiving treatment continuously; median overall survival was 19.3 months versus 18.3, respectively (P = .535).
RELATED: Adjuvant Docetaxel Fails to Improve Biochemical DFS in High-risk Prostate Cancer
The authors noted that although intermittent treatment was non-inferior for 1-year survival, it was deemed inferior for overall survival. Nonetheless it was concluded that intermittent docetaxel was well-tolerated and could be an option for patients with CRPC. Differences in progression-free survival and time to treatment failure were not significant between the 2 cohorts; safety profiles were comparable.
- Cash H, Steiner U, Heidenreich A, Klotz T, Melchior S, Albers P, et al. PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer. J Clin Oncol. 2016; 34 (suppl; abstr 5005).